News

People with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) typically experience a significantly delayed diagnosis — even with a family history positive for the disease, according to a nationwide study in Latvia. Indeed, the median delay in obtaining a diagnosis in the Northern European country is 20.5 years, researchers…

Long-term treatment with Takhzyro (lanadelumab) was associated with quality of life gains among people with hereditary angioedema (HAE) who participated in the HELP open-label long-term extension (OLE) study. The study’s participants, who either rolled over from the Phase 3 HELP trial (NCT02586805), or were newly enrolled in…

Pharvaris’ PHVS416, a soft-gel capsule of PHA121, now also known as deucrictibant, continues to show promising safety and effectiveness for treating swelling attacks in people with hereditary angioedema (HAE). That’s according to data from RAPIDe-1 (NCT04618211), a Phase 2 clinical trial that’s comparing on-demand treatment with PHVS416…

The use of preventive therapy in hereditary angioedema (HAE) was found to reduce the number of HAE attacks requiring on-demand treatment, and also had an impact on productivity, with patients losing fewer work or school days, a study in Australia reported. However, prophylactic treatment did not seem to ease…

A substantial proportion of adults with hereditary angioedema (HAE) in the Netherlands have poorly controlled disease, significantly affecting their quality of life, a survey study reported. Findings also linked well-controlled HAE to lower medical costs and greater productivity, relative to patients without adequate disease control. “Additional [preventive treatment] strategies…

Astria Therapeutics intends to move directly into a pivotal trial to support STAR-0215’s regulatory approval for hereditary angioedema (HAE) if proof-of-concept results from the ongoing Phase 1b/2 trial are positive, the company has announced. Initial results from the trial, called ALPHA-STAR (NCT05695248), are expected in mid-2024. With…

A 60-year-old man developed sudden angioedema as a result of losartan, a medication commonly used to treat high blood pressure, a U.S. case study reported. Losartan, sold under the brand name Cozaar, is often used to manage cardiovascular diseases and high blood pressure. To date, only a few…

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to NTLA-2002, an experimental gene-editing therapy that Intellia Therapeutics is developing to treat hereditary angioedema (HAE). RMAT designation is granted to therapies with the potential to treat, reverse, or cure serious or life-threatening…

Diagnosing and treating hereditary angioedema (HAE) can be challenging, but it is particularly difficult when patients live in rural areas of the U.S., a study based on a survey of allergy and immunology specialists reported. “Misdiagnosis of symptoms, access to a specialist, and affording medications remain…

Garadacimab, a preventive treatment candidate from CSL Behring, led to significant and clinically meaningful reductions in swelling attacks in patients with hereditary angioedema (HAE), according to published data from the Phase 3 VANGUARD clinical trial. The company expects to seek garadacimab’s approval from global health authorities later this…